Sorry, you need to enable JavaScript to visit this website.

Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose

Final Report: A Phase 3 Study to Assess the Persistence of hSBA Response up to 48 Months After Completion of a Primary Series of Bivalent rLP2086, and the Safety, Tolerability, and Immunogenicity of a Booster Dose of Bivalent rLP2086

Category & Conditions: Vaccine-related Conditions
Medicine: PF-05212366 (Bivalent rLP2086)
ClinicalTrials.gov Identifier (NCT): NCT01543087
Protocol ID: B1971033
    Share
PrintDownload
Open Plain Language Summary Result: Click here